ArticleBMC cancer2026
Thiostrepton potentiates chemotherapy-induced cell death in cisplatin-resistant SKOV3 cells.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundOne of the main problems in the treatment of ovarian cancer is resistance to the main drug (cisplatin). Thiostrepton (TST), a thiazole antibiotic, helps weaken cancer cells and enhance the efficacy of platinum-based therapy. This study examines the combination of TST and cisplatin in the SKOV3/CDDP model of resistance, focusing on associated changes in oxidative stress, mitochondrial function, genotoxicity, apoptosis, inflammatory mediators, and Wnt/β-catenin output.
methodsSKOV3/CDDP cells were treated with cisplatin at an IC50 concentration, TST at concentrations (1, 2.5, 5 µM), and the combination of these two substances for 24 h. Cell viability, intracellular energy, and membrane damage were measured by MTT and ATP assays and LDH release, respectively. Apoptosis was assessed using caspase-3/7 and TUNEL activity.DNA damage was analyzed using the Comet and CBMN assays. Oxidative stress and antioxidant defense were assessed by measuring ROS, MDA, GSH/GSSG ratio, and SOD, catalase, and GPx activities. Mitochondrial dysfunction (ΔΨm, NAD+/NADH), cytokines (IL-6, IL-8, TNF-α, IL-1β), and Wnt/β-catenin target genes (c-MYC, AXIN2) were evaluated.
resultsThe combination of cisplatin and TST was much more potent than when either was used alone. This combination increased oxidative stress processes, increased DNA damage, and decreased antioxidant capacity in cancer cells. Inflammatory cytokine levels were also increased, and c-MYC and AXIN2 expression were reduced, which was accompanied by the attenuation of β-catenin-dependent transcription.
conclusionOverall, TST increased the sensitivity of resistant ovarian cancer cells to cisplatin. Its anticancer effect was enhanced by oxidative-mitochondrial stress and DNA damage pathways, along with reduced Wnt/β-catenin transcription.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.